Bi-specific CAR-T cells, intended to reach both CD13 and T cell immunoglobulin and mucin-containing-3 (TIM3), have shown assurance in potentially eradicating AML while minimizing toxic damage to human BM stem cells (41). The gene discussed is HAVCR2; the disease is acute myeloid leukemia.